In 2,339 participants at the 12mg dose, the safety profile was consistent with TRIUMPH-4 and GLP-1 class expectations with one important improvement: discontinuation due to side effects dropped to 11.3% , compared to 18.2% in TRIUMPH-4's osteoarthritis population
Since semaglutide is a long-acting medication, it remains in your body for a significantly longer period than most medications
For example, the Academy of Nutrition and Dietetics recommends that breastfeeding moms lose weight gradually, at a rate of about one pound per week
According to J&J, Tremfya is the first and only fully-human, dual-acting monoclonal antibody for UC
Off (48 weeks): no administration, allowing a washout before any subsequent cycle
Check out his full take below #MetabolicHealth #Obesity #CarrumHealth Chief Network Officer | Network Architect | Healthcare Changemaker | Provider Quality Expert | Digital Health Analytics We're seeing a lot of employers and health plans struggle with the math on GLP-1 spend right now